Haddadin Yezan Munther 4

What Happened

• Haddadin Yezan Munther, a director of Outlook Therapeutics, reported a purchase of 34,000 shares of OTLK stock. The transaction is reported under code "P" (purchase) at $0.44 per share, for a total reported outlay of $14,960. This was a purchase (a net buy), which investors often view as a more informative signal than routine sales.

Key Details

• Transaction date: 2026-05-26; Filing date: 2026-05-27 (Form 4 accession 0001649989-26-000003)
• Price per share: $0.44; Shares acquired: 34,000; Total value: $14,960
• Transaction code: P = Purchase (open market or private purchase as reported)
• Shares owned after transaction: Not disclosed in the provided filing excerpt
• Footnotes/plan: No 10b5-1 plan, tax withholding, or other footnotes disclosed in the provided data
• Timeliness: Filed the next day — appears to be timely (not flagged as late)

Context

• This is a relatively small-dollar insider purchase (~$15k) reported by a company director. Purchases can be interpreted as a positive signal, but size and context matter; the filing alone does not reveal motive or broader ownership changes.